Identifying the best treatment for pancreatic cancer based on tumor characteristics
Project 3: Transcriptomic subtypes, response predictions, and therapy selection
This study is looking to help people with metastatic pancreatic cancer find the best treatment for them by figuring out the specific type of their cancer, so they can see if they might respond better to either FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10911134 on NIH RePORTER |
What this research studies
This research focuses on improving treatment selection for patients with metastatic pancreatic cancer by identifying molecular subtypes of the disease. It aims to determine which patients are more likely to respond to specific therapies, particularly comparing FOLFIRINOX and gemcitabine plus nab-paclitaxel (GnP). By using a CLIA-approved assay called PurIST, the study will prospectively evaluate how well this classifier can guide treatment decisions. This approach seeks to match patients with the most effective first-line therapy based on their tumor's characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic pancreatic cancer who are starting first-line treatment.
Not a fit: Patients with non-metastatic pancreatic cancer or those who have already received multiple lines of treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promise in using molecular subtyping to guide treatment decisions in cancer, indicating that this approach may be effective.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Yeh, Jen Jen — Univ of North Carolina Chapel Hill
- Study coordinator: Yeh, Jen Jen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.